| Health Care Product CAS 137986-29-9 and lower price SR9009 for lossing weight |
 |
| Health Care Product CAS 137986-29-9 and lower price SR9009 for lossing weight |
 |
| 1379686-29-9 |
 |
Health Care Product CAS 137986-29-9 and lower price SR9009 for lossing weight
1. Base Date
Name: SR9009
CAS No.: 1379686-29-9Molecula
r formular: C20H24ClN3O4S
2. Details of SR9009
Superlist Name: SR9009
Molecular Formula: C20H24ClN3O4S
CAS No.: 1379686-30-2
Purity: 99%
Synonyms: Ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate
Molecular Weight: 437.94
Appearance: White powder
Application: SR9009 increase exercise endurance and loss weight
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonistof Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ.
Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
SR9009: The New Drug That Could Boost Exercise Tolerance
A new drug known as SR9009, which is presently under development at TSRI (The Scripps Research Institute) has been shown to considerably boost exercise endurance in animal models. Scientists think these discoveries may lead to improved cures for individuals suffering from illnesses that severely limit exercise endurance such as obesity, COPD (chronic obstructive pulmonary disease), congestive heart failure and also in the deterioration of muscle capacity linked with aging.
SR9009: A Drug That Might Cause A Major Breakthrough in Fitness
The drug was developed by Professor Thomas Burris who found that it was capable of reducing obesity in animal models, particularly mice. SR9009 which is an easy to dose oral compound can increase the level of metabolic activity in skeletal muscle of mice. The treated mice became lean, developed larger muscles and had a 50% increase in running abilities which imitates the effects of aerobic exercise.
The SR9009 binds to Rev-erbα (one of the body's natural molecules) which influences lipid and glucose metabolism in the liver, the creation of fat-storing cells and the reaction of macrophages (cells that eliminate dying or dead cells) during inflammation.
Introduction : SR9009, which is currently under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice. Treated mice become lean, develop larger muscles and can run much longer distances simply by taking SR9009, which mimics the effects of aerobic exercise. If similar effects can be obtained in people, the reversal of obesity, metabolic syndrome, and perhaps Type-II diabetes might be the very welcome result.
The drug was developed by Professor Thomas Burris, who found that it was able to reduce obesity in populations of mice. It binds to and activates a protein called Rev-ErbAα, which influences fat and sugar burning in the liver, production of fat cells, and the body's inflammatory response.
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
Standard:USP
Competitive Advantage:
1 High quality with competitive price:
1) Standard: Enterprise Standard
2) All Purity≥98%
3) We are manufacturer and can provide high quality products with factory price.
2 Fast and safe delivery:
1) Parcel can be sent out in 24 hours after payment. Tracking number available
2) Secure and discreet shipment. Various transportation methods for your choice.
3) Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.
3 We have clients throughout the world:
1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2) Market feedback and goods feedback will be appreciated, meeting customers' requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.
Email:sales09 at ycphar dom com
Skype:sales09_109
Telephone:86-027-50756084
Mobile:86-18872220656
|
 |
Health Care Product CAS 137986-29-9 and lower price SR9009 for lossing weight
1. Base Date
Name: SR9009
CAS No.: 1379686-29-9
Molecular formular: C20H24ClN3O4S
2. Details of SR9009
Superlist Name: SR9009
Molecular Formula: C20H24ClN3O4S
CAS No.: 1379686-30-2
Purity: 99%
Synonyms: Ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate
Molecular Weight: 437.94
Appearance: White powder
Application: SR9009 increase exercise endurance and loss weight
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonistof Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ.
Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
SR9009: The New Drug That Could Boost Exercise Tolerance
A new drug known as SR9009, which is presently under development at TSRI (The Scripps Research Institute) has been shown to considerably boost exercise endurance in animal models. Scientists think these discoveries may lead to improved cures for individuals suffering from illnesses that severely limit exercise endurance such as obesity, COPD (chronic obstructive pulmonary disease), congestive heart failure and also in the deterioration of muscle capacity linked with aging.
SR9009: A Drug That Might Cause A Major Breakthrough in Fitness
The drug was developed by Professor Thomas Burris who found that it was capable of reducing obesity in animal models, particularly mice. SR9009 which is an easy to dose oral compound can increase the level of metabolic activity in skeletal muscle of mice. The treated mice became lean, developed larger muscles and had a 50% increase in running abilities which imitates the effects of aerobic exercise.
The SR9009 binds to Rev-erbα (one of the body's natural molecules) which influences lipid and glucose metabolism in the liver, the creation of fat-storing cells and the reaction of macrophages (cells that eliminate dying or dead cells) during inflammation.
Introduction : SR9009, which is currently under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice. Treated mice become lean, develop larger muscles and can run much longer distances simply by taking SR9009, which mimics the effects of aerobic exercise. If similar effects can be obtained in people, the reversal of obesity, metabolic syndrome, and perhaps Type-II diabetes might be the very welcome result.
The drug was developed by Professor Thomas Burris, who found that it was able to reduce obesity in populations of mice. It binds to and activates a protein called Rev-ErbAα, which influences fat and sugar burning in the liver, production of fat cells, and the body's inflammatory response.
SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.
Standard:USP
Competitive Advantage:
1 High quality with competitive price:
1) Standard: Enterprise Standard
2) All Purity≥98%
3) We are manufacturer and can provide high quality products with factory price.
2 Fast and safe delivery:
1) Parcel can be sent out in 24 hours after payment. Tracking number available
2) Secure and discreet shipment. Various transportation methods for your choice.
3) Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.
3 We have clients throughout the world:
1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2) Market feedback and goods feedback will be appreciated, meeting customers' requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.
Email:sales09 at ycphar dom com
Skype:sales09_109
Telephone:86-027-50756084
Mobile:86-18872220656
|
|
|
|
|
